Emiro Caicedo-Granados, MD

Dr. Caicedo Granados is a native of Colombia, South America. He completed his otolaryngology residency training at Universidad Militar Nueva Granada in Bogota Colombia. He moved to the United States to pursue additional training. He joined the otolaryngology Department at the University of Minnesota in the year 2000 as an NIH T32 research fellow. He then completed his Otolaryngology head and neck surgery training at the University of Minnesota. Following his residency training at the University of Minnesota, Dr. Caicedo Granados completed his advanced training in oncologic head and neck surgery and oncologic skull base surgery at the University of Pittsburgh.

Expertise

• Oncologic Head and Neck Surgery
• Oncologic Skull Base Surgery

Board Certifications

American Board of Otolaryngology

Awards & Recognition

• American Association for Cancer Research Minority Award in Cancer Research
• Cancer Research and Prevention Foundation Fellowship Award
• Minnesota Medical Foundation Resident Textbook Award

Professional Associations

• North American Skull Base Society
• American Head and Neck Society
• American Academy of Otolaryngology
• Minnesota Academy of Otolaryngology
• American Skull Base Society, Research Committee

Research Summary

Dr. Caicedo Granados developed the first murine model of laryngeal cancer described in the literature. This model has a great potential for evaluating new agents for chemoprevention and treatment of laryngeal carcinoma. He also works on developing therapeutic strategies for reactivating wild-type p53 in HPV (human papilloma virus) oropharyngeal squamous cell carcinoma.

Publications

To review peer-reviewed publications follow the link below

https://www.ncbi.nlm.nih.gov/sites/myncbi/1hY5hyGTG4EAq/bibliography/48458816/public/?sort=date&direction=ascending

1. Caicedo-Granados E, Lin R, Fujisawa C, et al. Wild-type p53 reactivation by small molecule Minnelide in human papilloma virus (HPV)-positive head and neck squamous cell carcinoma. Oral Oncology 2014;(14): 274-7
2. Caicedo-Granados E, Galbraith AR, Schachern MG et al. N-methylnitrosourea induced carcinoma as a model for larynx carcinogenesis. Head and Neck. 2014 Dec: 36(12): 1802-6
3. Kasemsiri P, Carrau RL, Otto BA et al. Reconstruction of the pedicled nasoseptal flap donor site with a contralateral reverse rotation flap: Technical modifications and outcomes. Laryngoscope 2013. Nov;123(11):2601-4
4. Caicedo-Granados E, Beswick DM, Christopoulos A et al. Oncologic and functional outcomes of partial laryngeal surgery for intermediate-stage laryngeal cancer. Otolaryngol Head Neck Surg 2013; 148:235-242.
5. Caicedo-Granados EE, Wuertz BR, Ondrey FG. Enforced expression of nuclear factor kappa B in p53 deficient keratinocytes induces cell cycle, angiogenic potential and tumorigenesis. Oral Oncol 2012; 48:303-310.
6. Beswick DM, Vaezi A, Caicedo-Granados E, Duvvuri U. Minimally invasive surgery for parapharyngeal space tumors. Laryngoscope 2012; 122:1072- 1078.
7. Caicedo-Granados EE, Wuertz BR, Marker PH, Lee GS, Ondrey FG. The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-kappaB inhibition. Arch Otolaryngol Head Neck Surg 2011; 137:799-805.
8. Lin J, Guan Z, Wang C et al. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res 2010; 16:77-87.
9. Caicedo-Granados E, Carrau R, Snyderman CH et al. Reverse rotation flap for reconstruction of donor site after vascular pedicled nasoseptal flap in skull base surgery. Laryngoscope 2010; 120:1550-1552.
10. Djalilian HR, Caicedo E, Lessan K et al. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats. Cancer Immunol Immunother 2007; 56:1207-1214.
11. Preciado D, Caicedo E, Jhanjee R et al. Pseudomonas aeruginosa lipopolysaccharide induction of keratinocyte proliferation, NF-kappa B, and cyclin D1 is inhibited by indomethacin. J Immunol 2005; 174:2964-2973.